A Decrease font size. A Reset font size. A Increase font size.

FDA approves new disease-modifying therapy

Photo of Plegridy autoinjector Pen used to administer disease-modifying therapy.

Photo courtesy of Biogen Idec.

Plegridy (peginterferon beta-1a, manufactured by Biogen Idec) is the newest disease-modifying therapy, or DMT, to be approved by the Food & Drug Administration for relapsing-remitting multiple sclerosis. This makes it the 11th DMT now available to people living with MS.

Injected under the skin every two weeks, Plegridy is designed to maintain the effects of interferon in the body for a longer period of time. It belongs to the same interferon class as several other DMTs available to people with MS and has a similar safety profile. However, individuals who have a history of hypersensitivity to natural or recombinant interferon beta or peginteferon should discuss other options with their healthcare provider.


Winter 2014–15


To learn more about Plegridy as a treatment for relapsing-remitting MS, ask your doctor or visit nationalMSsociety.org/plegridy.
image_printPrint this article
SinglePage Video
Singlepage video

Get the latest on MS research, advocacy efforts and more.

Get emails  

Download the free Momentum app from the Apple and Android stores.

Apple   Android